Daniel T. Schmid

Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck.

Objective To evaluate the impact of 18F‐fluoro‐deoxy‐glucose positron emission tomography after standard diagnostic workup in patients with advanced head and neck squamous cell carcinoma on staging and radiation treatment planning.

Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity

The aim of this study is to evaluate the additional clinical information provided by whole body positron emission tomography (PET) with fluorodeoxyglucose (FDG) for initial staging of patients with squamous cell carcinoma (SCC) of the oral cavity. PET scans from the head to the pelvic floor of 34 consecutive patients (22 male, 12 female; mean age 71 years) with histologically confirmed SCC of the oral cavity were retrospectively evaluated. Clinical information including CT of the head and neck and chest X-Ray or chest CT was compared with information on nodal involvement and distant metastases or secondary tumours obtained with PET. The primary tumour was identified with PET in 33 of 34 patients (97%). In 27 Patients (81%) the clinical N-stage was confirmed with PET. In two Patients (6%) additional pathologic loco-regional lymph nodes were found. In five patients more lymph nodes were identified with CT. Distant lesions were seen with PET imaging in bone, lung, mediastinum, liver and colon. In three patients (6%) distant metastases were correctly identified. In another four patients (12%) a secondary cancer was detected. One false positive finding was described with PET. In five of 34 patients (15%) the additional findings as revealed with PET lead to a change of treatment. Whole body PET provides relevant additional information to a standard clinical staging procedure in patients with oral cavity SCC. The detection of distant metastases and secondary primary tumours can have a great impact on patient management.

The value of 18F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma

The aims of this study were to assess a cohort of patients with head and neck squamous cell carcinoma (HNSCC) for: (1) the prevalence of synchronous distant metastases (DM) as detected by the initial staging by using (18)F-FDG PET/CT, (2) the prevalence of metachronous DM, and (3) the validity of published risk factors with special emphasis on the maximum standardized uptake value (SUV max) for the prediction of DM. Two hundred and ninety nine patients with advanced HNSCC were included. Following risk factors at the time of diagnosis and during follow-up were analyzed: advanced T/N stage, poor histological differentiation, level IV/Vb lymph nodes, primary site in the larynx/hypopharynx, and SUV max. The prevalence of DM at initial staging and during follow-up was 10% and 11%, respectively. At initial staging, primary site in the larynx/hypopharynx and neck nodes in level IV/Vb, and during follow-up only level IV/Vb nodes achieved statistical significance. The sensitivity for (18)F-FDG PET/CT with regard to the detection of DM was 96.8%, the specificity 95.4%, the positive predictive value (PV) 69.8%, and the negative PV 99.6%. Patients without DM showed a significantly better overall survival (OS) than patients developing DM (p<0.001). There was no significant difference in OS with regard to the time of diagnosis of DM. The prevalence for synchronous and metachronous DM in advanced HNSCC is considerable. (18)F-FDG PET/CT is highly accurate for initial staging and follow-up. DM carries a bad prognosis regardless of the time of diagnosis.

Contrast-enhanced 18F-FDG-PET/CT for the assessment of necrotic lymph node metastases

Cystic lymph node metastasis (CLNM) is commonly found in human papillomavirus (HPV)‐associated tonsillar squamous cell carcinoma (SCC). The aim of this study was to compare the accuracy in detecting cystic lymph node metastasis from tonsillar SCC between contrast‐enhanced CT, 18F‐ fluorodeoxyglucose‐positron emission tomography (FDG‐PET), non‐enhanced 18F‐FDG‐PET/CT, and contrast‐enhanced 18F‐FDG‐PET/CT.

Increased 18F-FDG uptake mimicking thyroid cancer in a patient with Hashimoto's thyroiditis

Abstract. We report the case of a 68-year-old patient with a known paravertebral malignant schwannoma, sent to us for postoperative staging. A combined whole-body PET/CT scan showed only poor 18F-fluorodeoxyglucose uptake in the region of the primary tumor but distinct increased fluorodeoxyglucose uptake in the left and right thyroid gland. Thyroid sonography showed two hypoechogenic nodules. Ultrasound-guided fine-needle aspiration biopsy of one nodule showed oxyphil transformed cells, compatible with malignancy. Based on these findings, the patient underwent a subtotal thyroidectomy. Histopathology of the specimen revealed a chronic follicular Hashimotos thyroiditis. This case demonstrates that Hashimotos thyroiditis can mimic thyroid cancer in PET but also in sonography and fine-needle aspiration biopsy.

Influence of Bowel Preparation Before 18F-FDG PET/CT on Physiologic 18F-FDG Activity in the Intestine

Our objective was to investigate the use of bowel preparation before 18F-FDG PET/CT to reduce intestinal 18F-FDG uptake. Methods: Sixty-five patients with abdominal neoplasias were assigned either to a bowel-preparation group (n = 26) or to a native group (n = 39). 18F-FDG activity was measured in the small intestine and the colon. Results: In the 26 patients with bowel preparation, average maximal standardized uptake value (SUVmax) was 3.5 in the small intestine and 4.4 in the colon. In the 39 patients without bowel preparation, average SUVmax was 2.6 in the small intestine and 2.7 in the colon. 18F-FDG activity impaired diagnosis in 6 patients (23%) in the bowel-preparation group and 11 patients (28%) in the native group (P = 0.5). SUVmax in the colon was significantly higher in the bowel-preparation group (P = 0.002), but SUVmax in the small intestine did not significantly differ between the 2 groups (P = 0.088). Conclusion: Bowel preparation increases 18F-FDG activity in the large intestine and is therefore not useful before PET/CT.

Fatty Muscle Atrophy: Prevalence in the Hindfoot Muscles on MR Images of Asymptomatic Volunteers and Patients with Foot Pain

PURPOSE To determine prevalence and degree of fatty muscle atrophy in plantar foot muscles in asymptomatic volunteers and in patients with foot pain. MATERIALS AND METHODS Institutional review board approval and informed consent were obtained. The prevalence and degree of fatty muscle atrophy were evaluated with magnetic resonance imaging in the abductor digiti minimi (ADM), flexor digitorum brevis (FDB), abductor hallucis (AH), and quadratus plantae (QP) muscles in 80 asymptomatic volunteers (mean age, 48 years; range, 23-84 years) and 80 patients with foot pain (mean age, 48 years; range, 20-86 years). Muscles were characterized as normal (grade 0) or as having mild (grade 1) or substantial (grade 2) fatty atrophy by two readers separately. Results of visual grading for both readers were compared by using the Mann-Whitney test. Associations between age and degree of fatty muscle atrophy were assessed by using the Kruskal-Wallis test. RESULTS Readers 1 and 2 found substantial fatty atrophy of the ADM muscle in four (5%) and five (6%) volunteers, respectively, and in three (4%) and nine (11%) patients, respectively. One reader diagnosed substantial fatty atrophy of the AH muscle in three (4%) volunteers and of the FDB muscle in two (2%) volunteers. Prevalence for the QP muscle varied between 0% and 1%. An association between age and degree of fatty atrophy of the ADM muscle was found for volunteers by both readers and for patients by reader 1 (P < .01). CONCLUSION Prevalence of fatty muscle atrophy of the ADM muscle-classically considered to represent entrapment neuropathy-is between 4% and 11% in both asymptomatic volunteers and patients with foot pain, and it increases with age.

Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine.

Objective: To analyze the effect of H1N1 influenza A virus vaccination in patients referred for staging or follow-up F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for different malignant tumors. Method and Materials: Medical history of all patients scheduled for FDG PET/CT during the national vaccination campaign against H1N1 was evaluated for recent vaccination. Site of injection and time between PET/CT and the date of vaccination (dTime) was determined. A difference in the maximum SUV between ipsi- and contralateral deltoid muscle or axillary lymph node of more than 0.5 was determined as positive reaction. The best cut-off dTime for still visible reaction was calculated. All patients with positive ipsilateral lymph node were clinically followed. Institutional Review Board approval was waived. Results: Of 269 patients, 58 (21.5%) were vaccinated for the H1N1 within 4 weeks prior to PET/CT (mean, 14.5 ± 8.7 days). Of them, 17 (29.3%) patients had FDG-positive lymph nodes (mean SUV, 1.43 ± 1.06), with a dTime range from 1 to 14 days. Only 2 of them had no increased FDG uptake in the ipsilateral deltoid muscle. The area under the receiver operator characteristic curve revealed a strong relation between time delay (dTime) and axillary activity (AUC, 0.9; 95% confidence interval, 0.816–0.983) with a cutoff at 8 days (Youden Index). At follow-up (mean, 183 days; range, 173–196 days), no patient was found to have required treatment or signs of axillary lymphadenopathy. Conclusions: H1N1 vaccination can cause false-positive FDG PET/CT findings, when administered less than 14 days before the test, with the highest probability if the vaccination was administered less than 8 days ago. Increased FDG activity in the ipsilateral deltoid muscle is a key finding for accurate interpretation of increased FDG activity in axillary lymph nodes.

Physiologic [18F]fluorodeoxyglucose uptake of floor of mouth muscles in PET/CT imaging: a problem of body position during FDG uptake?

Abstract Objective: Assess the influence of 2 different patient positions during [18F]fluorodeoxyglucose (FDG) uptake phase on physiologic FDG accumulation of the floor of mouth (FOM) muscles. Study design: A prospective study design was used. Methods: Two hundred prospectively enrolled patients were included in the study: (a) head and neck cancer (HNC) patients in supine or (b) sitting position, (c) patients with other malignant tumours in supine or (d) sitting position. An intra-individual analysis was done on patients (b) and (d) when such scans were available. Maximum standardized uptake values without correction and corrected for blood pool activity were assessed. Results: The inter-individual analysis (sitting vs supine) revealed no significant differences (P = 0.17 and P = 0.56). The subgroup analysis on the patients with HNC (P = 0.56 and P = 0.15) and in patients with other malignancies (P = 0.14 and P = 0.08) revealed no significant difference; neither did the intra-individual analysis. Conclusions: The supine or sitting position during the uptake phase for FDG-positron emission tomography/computed tomography has no effect on the amount and distribution of physiologic FDG activity in the muscles of the FOM.

Combined PET/CT-perfusion in patients with head and neck cancers might predict failure after radio-chemotherapy: a proof of concept study

Background[18F]FDG-PET/CT imaging is broadly used in head and neck cancer (HNSCC) patients. CT perfusion (CTP) is known to provide information about angiogenesis and blood-flow characteristics in tumors. The aim of this study was to evaluate the potential relationship of FDG-parameters and CTP-parameters in HNSCC preand post-therapy and the potential prognostic value of a combined PET/CT with CTP.MethodsThirteen patients with histologic proven HNSCC were prospectively included. All patients underwent a combined PET/CT with integrated CTP before and after therapy. Pre- and post-therapeutic data of CTP and PET of the tumors were compared. Differences were tested using Spearman’s rho test and Pearson’s correlation. A p-value of p <0.05 was considered statistically significant. Correlations were calculated using Pearson’s correlation. Bootstrap confidence intervals were calculated to test for additive confidence intervals.ResultsThree patients died due to malignancy recurrence, ten patients were free of recurrence until the end of the follow-up period. Patients with recurrent disease had significantly higher initial CTP-values compared to the recurrence-free patients: BFpre 267.4 (171.2)ml/100 mg/min, BVpre 40.9 (8.4)ml/100 mg and MTTpre 8.2 (6.1)sec. No higher SUVs initially but significantly higher TLG compared to patients without recurrence were found. Post-therapeutic PET-values differed significantly between the two groups: SUVmaxpost 6.0 (3.2), SUVmeanpost 3.6 (2.0) and TLG 21751.7 (29794.0).ConclusionIn our proof of concept study, combined PET/CT with integrated CTP might show complementary prognostic data pre- and post chemo-radiotherapy. CTP may be used to predict local tumor recurrence, while FDGPET/CT is still needed for whole-body staging.